Pharma’s Missing Out on Social Media Says Worldcom Report
The Worldcom Public Relations Group, a global partnership of independent public relations firms, conducted research that suggests many large pharmaceutical companies are not taking advantage of online and social media communications. The report, Digital Health Monitor, identifies how 25 global pharma firms manage their online and social media presence globally and in 20 countries.
The report ranks each company in terms of their presence on, and the use of, Apps, Blogs Facebook, Flickr, Instagram, LinkedIn, Pinterest, Tumblr, Twitter and YouTube. It also reviewed the use of these channels by country. Pfizer, for example, came out on top for the use of YouTube, while Novartis ranked as top user for LinkedIn. The report found, however, that none of the companies used these channels to maximum advantage.
Download the full report here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
